2026-01-12 - Analysis Report
**Company Overview:** Schrodinger Inc. specializes in molecular simulation, discovery, and development of therapeutics by harnessing the power of artificial intelligence.

**Financial Report:**

#### Return Rate Comparison

* Review Stock (SDGR):
	+ Cumulative Return: -53.37%
* Comparison Stock (VOO):
	+ Cumulative Return: 67.27%
* Divergence:
	+ Current: -120.60
	+ Relative Divergence: 1.00%

#### Alpha, Beta Analysis

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2021-2023  | -57.0% | 52.9% | -58.0% | 1.8 | 2.6B |
| 2022-2024  | 6.0% | 46.6% | -13.0% | 1.8 | 1.4B |
| 2023-2025  | -4.0% | 46.6% | -66.0% | 1.8 | 1.3B |

### Recent Stock Price Fluctuations

* Close: $18.39
* Last-Market:
	- Price: $18.39
	- Previous Close: $18.61
	- Change: -$1.18
* 5-Day SMA: $18.61
* 20-Day SMA: $18.20
* 60-Day SMA: $18.67

### Technical Indicators

* Market Risk Indicator (MRI): 0.70
* RSI: 61.51
* PPO: 0.39
* Hybrid Signal: Buy (Cash 0%)
* Risk Level: Medium (MRI 0.70)
* Recent (20 days) relative divergence change: -1.20 (worsening)
* 7-day Rank change: 0 (flat)
* 7-day Dynamic Expected Return change: -3561.30 (worsening)
* Expected Return: -6400.50%

### Recent News & Events

[2025-12-22] BofA Upgrades Schrödinger (SDGR) to Buy After Strategic Pivot to Software - Yahoo Finance
[2026-01-09] Is Schrödinger’s TuneLab AI Integration Reshaping the Investment Case For SDGR? - simplywall.st
[2026-01-07] SDGR: UBS Initiates Coverage with Neutral Rating | SDGR Stock Ne - GuruFocus
[2026-01-09] Eli Lilly in pact with Schrödinger in AI-related drug discovery - Seeking Alpha
[2026-01-07] UBS Initiates Coverage of Schrödinger (SDGR) with Neutral Recommendation - Nasdaq
[2026-01-07] Wall Street Analysts Believe Schrodinger (SDGR) Could Rally 46.17%: Here's is How to Trade - Eastern Progress

### Analyst Opinions

Analyst Consensus:
- Key: Buy
- Mean (1=StrongBuy~5=Sell): 1.60 (~Buy)
- Opinions: 10
- Target Price (avg/high/low): 25.00 / 32.00 / 18.00

### Recent Earnings Analysis

| Date | EPS | Revenue |
|---|---:|---:|
| 2025-11-05 | -0.45 | 0.05 B$ |
| 2025-08-06 | -0.59 | 0.05 B$ |
| 2025-05-07 | -0.82 | 0.06 B$ |
| 2024-11-12 | -0.52 | 0.04 B$ |
| 2025-11-05 | -0.52 | 0.04 B$ |

The quarterly earnings analysis shows a decline in EPS and revenue in consecutive quarters, indicating a struggling financial performance.

### Financial Information

#### Revenue and Profitability

| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2025-09-30 | $0.05B | 51.61% |
| 2025-06-30 | $0.05B | 47.77% |
| 2025-03-31 | $0.06B | 52.26% |
| 2024-12-31 | $0.09B | 72.61% |
| 2024-09-30 | $0.04B | 50.24% |

The revenue and profitability analysis shows a slight decline in revenue and profit margin in the last two quarters, indicating a potential slowdown in business growth.

#### Capital and Profitability

| Quarter | Equity | ROE |
|---------|---------|-----|
| 2025-09-30 | $0.32B | -10.21% |
| 2025-06-30 | $0.34B | -12.59% |
| 2025-03-31 | $0.37B | -16.01% |
| 2024-12-31 | $0.42B | -9.54% |
| 2024-09-30 | $0.45B | -8.49% |

The capital and profitability analysis shows a decline in equity and return on equity (ROE) in consecutive quarters, indicating a weakening capital structure and profitability.

### Comprehensive Analysis

Based on the analysis of return rate, technical indicators, earnings, and financial information, it appears that Schrodinger Inc. is facing challenges in its financial performance, with declining revenue, profitability, and capital structure. The recent news and events suggest potential opportunities, but the technical indicators and analyst opinions also indicate caution. Overall, the comprehensive analysis suggests a cautious approach to investing in Schrodinger Inc.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.